S OF SCIENTIFIC MISCONDUCT RELEASE Time: March 24 2003
S OF SCIENTIFIC MISCONDUCT RELEASE Time: March 24 2003 See: NOT-OD-03-037 Section of Health insurance and Individual Providers (DHHS) Notice is hereby considering that any office of Analysis Integrity (ORI) as well as the Performing Helper Secretary for Wellness have taken last action in the next case: Justin Radolf M. Pathogenesis involved in technological misconduct in analysis supported by Country wide Institute of Allergy and Infectious Illnesses (NIAID) Country wide Institutes of Wellness (NIH) offer R01 AI29735-11 and included false claims right into a offer program entitled “Tick Inhibitors of Hemostatis: Book Therapeutic Agencies and an Anti-Tick Vaccine” to america Section of Agriculture (USDA). Dr. Radolf falsified and fabricated preliminary research data to falsely claim that the genes that he proposed to characterize were specifically expressed in the tick salivary gland. Dr. Radolf represented the products of control samples as positive assessments for mRNA expression HMN-214 from different genes and offered data as positive for genes that had not been tested. Specifically PHS finds that Dr. Radolf falsified and Rabbit Polyclonal to USP43. fabricated data in January 2000 by altering the labeling of a figure included in a USDA grant application and by falsifying the text in both the USDA application and in an overlapping application to a state-sponsored program. This incident of HMN-214 falsification and fabrication is usually significant because the data was the first direct evidence that this isolated clones represented genes expressed in tick salivary gland and therefore represented proteins that could be targets of vaccine development to protect the hosts from tick- transmitted microbial diseases. The misinformation of the extent of the progress in this project had the potential to mislead grant reviewers and the scientific community about an area of research that could have led to the prevention of Rocky Mountain Spotted Fever and other tick-transmitted diseases. The Respondent submitted the following admission to ORI: In January of 2000 I engaged in scientific misconduct involving research supported by the National Institutes of Health. The misconduct occurred during the preparation of grant proposals submitted to the United States Department of Agriculture and Connecticut Innovations Inc. More specifically I falsified and fabricated preliminary data by intentionally altering the labeling of an ethidium bromide-stained agarose gel purporting to demonstrate the expression of genes in the salivary glands of feeding Dermacentor andersoni ticks. HMN-214 In so doing I misrepresented the products of control samples as positive assessments for the presence of mRNAs derived from unrelated genes and I fabricated data to show the expression of genes that in fact were not tested. The texts of the two proposals also contained inaccurate statements relating to these falsified and fabricated data. By inaccurately portraying the extent of our progress in characterizing salivary gland proteins that might interfere with tick feeding my actions would have misled the reviewers of the proposals into thinking that we were closer to the development of an anti-tick vaccine than we actually were. Truthfulness in the recording presentation and reporting of data-the accuracy and reliability of the research record-is the foundation of all scientific research. By misrepresenting primary results intentionally in both offer proposals my actions violated this basic precept affected my scientific integrity and positioned my 20-year job as a biomedical researcher in danger. My activities could HMN-214 possess affected also the careers and integrity of people with whom I work individuals who place their trust me and who turn to me for scientific leadership. I consider comprehensive and complete responsibility because of this misconduct. I dedicated this wrongful act without prompting by various other all those and without the consent or understanding of others. I am remorseful for my behavior and provide my deeply most powerful assurance towards HMN-214 the functioning office of Analysis Integrity that it’ll hardly ever recur. Dr. Radolf provides entered right into a Voluntary Exclusion Contract where he provides voluntarily decided for an interval of five (5) years starting on March 10 2003 (1) to exclude himself from portion in virtually any advisory capability to PHS including however not limited to program on any PHS advisory committee plank and/or peer review committee or being a expert; (2) that any organization which submits a credit card applicatoin for PHS support for a study project which Dr. Radolf’s involvement is suggested or which uses Dr. Radolf in virtually any capability on HMN-214 PHS-supported analysis or that submits a written report of PHS-funded analysis in.